Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omacor (Pronova BioPharma)
- Development stage
- Unknown
- Lead developer
- BASF
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omacor is a pharmaceutical-grade concentrate of omega-3 acid ethyl esters, primarily composed of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio of approximately 1:2, with added alpha-tocopherol as an antioxidant. Developed by Pronova BioPharma, it is indicated for the treatment of hypertriglyceridemia and has been extensively studied for secondary prevention of cardiovascular events following myocardial infarction. The drug exerts its therapeutic effects by reducing hepatic triglyceride synthesis through the inhibition of diacylglycerol O-acyltransferase (DGAT) and increasing fatty acid beta-oxidation via the activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha). Additionally, it modulates inflammatory pathways and stabilizes myocardial membranes, potentially reducing the risk of arrhythmias. The Helse Stavanger HF study specifically evaluated the impact of high-dose Omacor on cardiac events, serum lipids, and markers of inflammation and coagulation when administered early after an acute myocardial infarction.
- Brand names
- OmacorLovaza
- Other names
- Omega-3-acid ethyl estersOmega3-acid ethyl estersOmega 3-acid ethyl estersEPA + DHA ethyl estersn-3 fatty acids concentraten3 fatty acids concentraten 3 fatty acids concentrate
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)DGAT1 (Diacylglycerol O-acyltransferase 1)
Beyond the preview
Go deeper on Omacor (Pronova BioPharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omacor (Pronova BioPharma).